---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015590"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:39:38.216710+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety

## Summary
- Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.
- R&D expenses $2.8M (+215% YoY) driven by PH-762 clinical trial, CMC and toxicology costs.
- G&A expenses $1.4M (+39% YoY) on higher employee costs, investor outreach and professional fees.
- PH-762 dose-escalation study (22 patients) complete; final data being analyzed; FDA submission for next steps targeted Q2 2026.
- ATM agreement with H.C. Wainwright in April 2026 allows up to $6.36M in common stock sales.

## SEC filing metadata
- accession: 0001437749-26-015590
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/0001437749-26-015590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/phio20260331_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015590
- JSON: https://secwatch.observer/filing/0001437749-26-015590.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015590.txt

## Key facts
- Earnings Releases
  Phio Pharmaceuticals Corp. reported quarter ended March 31, 2026 results: net income $4.0 million.
  - Period: quarter ended March 31, 2026
  - Net income: $4.0 million
  - Result: reported results
  source text: 31, 2025. The increase in general and administrative expenses was primarily driven by employee related costs, investor outreach and professional fees. Net Loss Net loss was $ 4.0 million for the three months ended March 31, 2026 as compared with $1.8 million for the three months ended March 31, 2025. The increase in net loss was attributable to increases in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/0001437749-26-015590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.